104632-28-2

Basic information

• Product Name: (R)-Pramipexole
• Synonyms: (R)-4,5,6,7-Tetrahydro-N6-propyl-2,6-benzothiazolediamine;(R)-Pramipexole;R-(+)-Pramipexole;(R)-4,5,6,7-Tetrahydro-N6-propyl-2,6-benzothiazolediamine Dihydrochloride;(R)-Pramipexole Dihydrochloride;R-(+)-Pramipexole Dihydrochloride;Pramipexole Related Compound D (25 mg) ((R)-2-Amino-4,5,6,7-tetrahydro-6-(propylamino)benzothiazole);DexpraMipexole
• CAS NO: 104632-28-2
• Molecular Formula: C₁₀H₁₇N₃S
• Molecular Weight: 211.33
• Product Categories: All Inhibitors;Inhibitors;Intermediates & Fine Chemicals;Pharmaceuticals;Sulfur & Selenium Compounds;Chiral Reagents
• Mol File: 104632-28-2.mol
• Article Data: 6

Chemical Properties

• Melting Point: 270-272°C
• Boiling Point: 378.0±42.0 °C(Predicted)
• Appearance: /
• Density: 1.17±0.1 g/cm3 (20 ºC 760 Torr)
• Storage Temp.: -20°C Freezer, Under Inert Atmosphere
• Solubility: DMSO (Slightly), Methanol (Sparingly, Sonicated), Water (Slightly)
• PKA: 9.47±0.20(Predicted)
• CAS DataBase Reference: (R)-Pramipexole(CAS DataBase Reference)
• NIST Chemistry Reference: (R)-Pramipexole(104632-28-2)
• EPA Substance Registry System: (R)-Pramipexole(104632-28-2)

Safety Data

• Hazardous Substances Data: 104632-28-2(Hazardous Substances Data)

Usage

Description

(R)-Pramipexole, also known as the (R)-enantiomer of Pramipexole, is a chiral molecule that acts as a dopamine-D2-receptor agonist. It is a white to off-white solid with distinct pharmacological properties compared to its (S)-enantiomer counterpart. As an antiparkinsonian agent, it plays a crucial role in the treatment of Parkinson's disease by mimicking the effects of dopamine in the brain.

Uses

Used in Pharmaceutical Industry:
(R)-Pramipexole is used as an antiparkinsonian agent for the treatment of Parkinson's disease. It functions as a dopamine-D2-receptor agonist, helping to alleviate symptoms associated with the disorder by compensating for the reduced levels of dopamine in the brain.
Additionally, due to its distinct pharmacokinetics and pharmacodynamics compared to the racemic mixture or the (S)-enantiomer, (R)-Pramipexole may offer advantages in terms of efficacy, safety, and reduced side effects, making it a valuable compound for further research and development in the pharmaceutical industry.

Upstream product

• 106006-85-3 (+)-2-amino-6-propionamidotetrahydrobenzothiazole 
• 106006-83-1 2,6-diamino-4,5,6,7-tetrahydro-benzthiazole 
• 106092-11-9 (R)-4,5,6,7-tetrahydrobenzo[1,2-d]thiazole-2,6-diamine 
• 104617-86-9 2-amino-4,5,6,7-tetrahydro-6-propylaminobenzothiazole 
• 147-71-7 D-tartaric acid 
• 1332723-78-0 (R)-(+)-2-amino-4,5,6,7-tetrahydro-6-(n-propylamino)benzothiazole p-toluenesulfonic acid 

Downstream Products

• 104632-27-1 (R)-N6-propyl-4,5,6,7-tetrahydrobenzo[d]thiazole-2,6-diamine dihydrochloride 
• 1026084-24-1 (+)-2-(2-amino-4,5,6,7-tetrahydrobenzo[d]thiazol-6-yl)(propylamino)-1-(4-(2-methoxyphenyl)piperazin-1-yl)ethanone 
• 1026084-21-8 (+)-2-(2-amino-4,5,6,7-tetrahydrobenzo[d]thiazol-6-yl)(propylamino)-1-(4-phenylpiperazin-1-yl)ethanone 
• 1026084-25-2 (+)-2-(2-amino-4,5,6,7-tetrahydrobenzo[d]thiazol-6-yl)(propylamino)-1-(4-(2,3-dichlorophenyl)piperazin-1-yl)ethanone 

Relevant articles and documents

IMPROVED SYNTHESIS OF AMINE SUBSTITUTED 4,5,6,7-TETRAHYDROBENZOTHIAZOLE COMPOUNDS

The present invention is related to an improved process for the preparation of amino- substituted 4,5,6,7-tetrahydrobenzothiazole compounds of formula I, such as the compound 2- amino-4,5,6,7-tetrahydro-6-(n-propylamino)benzothiazole. The invention furthe

METHOD FOR THE RESOLUTION OF 2-AMINO-6-PROPYLAMINO-4,5,6,7-TETRAHYDROBENZOTHIAZOL AND INTERMEDIATE COMPOUNDS

The invention relates to a novel method for the resolution of the racemic mixture of compound (R,S)-2-amino-6-propylamino-4,5,6,7-tetrahydrobenzothiazole, or the enrichment of same with in one of its enantiomers, and to intermediate compounds which can be used to perform said method.

PROCESS FOR PREPARING CHIRALLY PURE 2-AMINO-6-(ALKYL)AMINO-4,5,6,7-TETRAHYDROBENZOTHIAZOLES BY LIQUID CHROMATOGRAPHIC RESOLUTION

Processes for obtaining single enantiomers of 2-amino-6-(alkyl)amino-4,5,6,7-tetrahydrobenzothiazoles by liquid chromatography are disclosed.